Tyrosine kinase inhibitors (TKIs) targeting BCR–ABL1 have significantly changed the overall survival rate of chronic myeloid leukemia (CML) patients. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.